REGN7075

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Advanced Solid TumorsColorectal CancerNon-Small Cell Lung CancerSolid Tumours

Phase 1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Active, not recruitingNCT04626635

Regeneron PharmaceuticalsAdvanced Solid Tumors

Start: 2020-12-21End: 2027-03-05Updated: 2026-07-02

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

RecruitingCTIS2022-501234-37-00

Regeneron Pharmaceuticals Inc.Solid Tumours

Start: 2024-05-07Target: 212Updated: 2025-09-16

Phase 2

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT06465329

Regeneron PharmaceuticalsNon-Small Cell Lung Cancer

Start: 2024-11-18End: 2030-05-02Target: 120Updated: 2026-08-24

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients with Resectable Non-Small Cell Lung Cancer

RecruitingCTIS2023-509806-31-00

Regeneron Pharmaceuticals Inc.Non-Small Cell Lung Cancer

Start: 2025-02-11Target: 40Updated: 2025-11-07

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

RecruitingNCT07281768

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsColorectal Cancer

Start: 2026-07-14End: 2030-07-01Target: 66Updated: 2026-07-21

Related Papers

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.

Journal of Clinical Oncology2024-06-017 citations

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Journal of Clinical Oncology2024-01-20

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Journal of Clinical Oncology2023-01-245 citations

735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results

Regular and Young Investigator Award Abstracts2022-11-013 citations

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-014 citations